CPC+CBEx Abstracts
On September 5–6, 2025, the annual Clinical Pathways Congress + Cancer Care Business Exchange convened clinical pathway innovators, researchers, payers, and other key stakeholders. In alignment with ongoing efforts to advance high-quality, evidence-based cancer care through the application of clinical pathways, authors contributed research that presented real-world evidence, conceptual models, and proposals designed to inform the development and refinement of oncology pathways.
Decision Support Documentation for Targeted Therapy Eligibility in Breast Cancer
Re-prompting providers within the Clear Value PlusTM clinical decision support system significantly improved documentation of AKT1, PTEN, and PIK3CA biomarkers and increased the use of precision therapies for hormone receptor–positive, HER2-negative breast cancer, demonstrating the value of integrated prompts in supporting guideline-concordant, personalized treatment decisions.
Modification of PARP Inhibitor Use in mCRPC With Co-Occurring BRCA1/2 Mutations and MSI-High Status
Following an update to the US Oncology Network’s Prostate Cancer Pathway reflecting evidence that BRCA1/2 mutations in microsatellite instability–high (MSI-H) tumors are typically monoallelic and not associated with PARP inhibitor sensitivity, clinical practice shifted significantly, highlighting the value of integrating genomic context into clinical decision support systems for precision oncology.
An environmental scan revealed that integrating psychosocial care into oncology programs—especially in underserved and rural communities—is hindered by systemic and structural barriers, prompting the development of a strategic four-part framework to improve mental health access and equity in cancer care.
The 5-year results of the OPTIC study demonstrate that a response-based dosing strategy of ponatinib provides sustained efficacy and manageable safety in patients with chronic-phase chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitors or with the T315I mutation.
In a retrospective evaluation of 6668 patients receiving oral oncology medications through an academic health system specialty pharmacy, pharmacist-led interventions were associated with improved therapy adherence, reduced treatment complications, and low rates of hospitalization and emergency department use, highlighting the clinical and operational value of integrated pharmacist management in complex cancer care.
In a pre-post study across 258 oncology clinics, integration of DeepScribe’s oncology-specific artificial intelligence (AI) scribe into the Flatiron Health OncoEMR electronic health record system resulted in high adoption (98%), increased diagnostic documentation and improved clinician workflow and satisfaction, supporting the scalability of AI-assisted documentation in complex cancer care.
Using a semi-Markov model from a US Medicare perspective, ibrutinib priced at the Centers for Medicare & Medicaid Services–negotiated maximum fair price was found to be cost-effective compared with acalabrutinib and zanubrutinib at current wholesale acquisition costs for both first-line (1L) and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), with dominant incremental cost-effectiveness ratios and consistent results across scenario and sensitivity analyses.
Provision of Comparative Clinical Evidence to Support Pathway Decision-Making
Initially developed to support the Pathways Task Force within the Value Pathways powered by the National Comprehensive Cancer Network, embedded evidence tables summarizing clinical trial data—including patient-reported outcomes—have seen significant growth in provider engagement across the US Oncology Network, underscoring their value as a real-world clinical decision support resource.
Assessing Clinical Pipe, EHR to EDC Data Transfer Solutions
In a pilot study at UChicago Medicine, Flatiron Clinical Pipe—a study-agnostic electronic health record (EHR)–to–electronic data capture (EDC) integration tool—automated the transfer of 4700 structured data points across two gastrointestinal oncology trials, saving approximately 35 hours of manual entry and demonstrating improvements in workflow efficiency.
Green Light, Red Flags: A New Framework for Evaluating Oncology Accelerated Approvals
To improve transparency and consistency in evaluating oncology therapies granted US Food and Drug Administration Accelerated Approval, Evolent developed the Clinical Benefit Index—a framework combining the European Society for Medical Oncology Magnitude of Clinical Benefit Scale with real-world modifiers— demonstrating its utility by reclassifying therapies in biliary tract cancer based on adjusted clinical value.
Streamlining Clinical Decision Support Through Integrated Education
To improve workflow efficiency and clinical decision-making, the Clear Value Plus clinical decision support tool integrated Launch N’ Learn—an embedded feature providing point-of-care access to staging criteria and guideline-based resources—resulting in 457 provider accesses within five months, with the highest engagement seen for hematologic malignancy tools such as the stage-modified International Prognostic Index.
Faced with rising operational costs and declining reimbursement, Radiation Business Solutions created a tax-exempt, bond-funded not-for-profit model to consolidate four independent for-profit cancer centers in Alaska, demonstrating that strategic recapitalization, unified governance, and nonprofit designation can ensure long-term oncology care access, financial sustainability, and enhanced community engagement.
From Approval to Action: Evaluating Review Timelines for Oncology Therapies in Value Pathways
A retrospective analysis of 84 oncology drug approvals from January 2024 to June 2025 demonstrated that the US Oncology Network’s Pathways Task Force (PTF) conducted timely reviews with most therapies discussed within 60 days, affirming the PTF’s capacity to efficiently integrate new evidence into clinical pathways.
For more highlights, speaker interviews, and in-depth coverage of the conference, visit the CPC+CBEx newsroom.
